BeOne Medicines (ONC) Income from Non-Controlling Interests (2017 - 2020)
BeOne Medicines (ONC) posted quarterly Income from Non-Controlling Interests of $96000.0 for Q4 2020, down 42.17% year-over-year from $166000.0 in Q1 2020, and up 106.89% quarter-over-quarter from -$1.4 million in Q3 2020.
Powered by 
Analysis
BeOne Medicines (ONC) Income from Non-Controlling Interests (2017 - 2020) Analysis & Trends
BeOne Medicines (ONC) has reported Income from Non-Controlling Interests for 4 consecutive years, with $96000.0 the latest figure, recorded in Q4 2020.
- In Q4 2020, Income from Non-Controlling Interests fell 42.17% year-over-year to $96000.0; the TTM figure through Sep 2021 stood at $96000.0 (up 102.71% YoY), while the FY2020 annual figure was -$3.6 million, down 85.49% from the prior year.
- Income from Non-Controlling Interests advanced to $96000.0 in Q4 2020 per ONC's latest filing, from -$1.4 million in the prior quarter.
- Across five years, Income from Non-Controlling Interests topped out at $1.5 million in Q4 2018 and bottomed at -$1.4 million in Q3 2020.
- Historically, Income from Non-Controlling Interests has averaged -$401666.7 across 4 years, with a median of -$429000.0 in 2019.
- On a YoY basis, Income from Non-Controlling Interests climbed as much as 3493.02% in 2018 and fell as far as 513.33% in 2018.
- BeOne Medicines' Income from Non-Controlling Interests stood at $43000.0 in 2017, then soared by 3493.02% to $1.5 million in 2018, then tumbled by 89.26% to $166000.0 in 2019, then slumped by 42.17% to $96000.0 in 2020.
- Business Quant data shows ONC's Income from Non-Controlling Interests at $96000.0 in Q4 2020, -$1.4 million in Q3 2020, and -$1.1 million in Q2 2020.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.62 Bn | 131.77 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.73 Bn | 77.73 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.53 Bn | 58.35 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.23 Bn | 53.09 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - | - |
| 6 | BeOne Medicines | 40.03 Bn | 34.93 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.50 Bn | 32.19 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.52 Bn | 27.68 Bn | - | 63.60 Mn |
| 9 | Insmed | 27.46 Bn | 26.30 Bn | 358.27 Mn | - |
| 10 | Incyte | 25.59 Bn | 21.05 Bn | 1.57 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2020 | 96,000.00 |
| Sep 30, 2020 | -1.39 Mn |
| Jun 30, 2020 | -1.12 Mn |
| Mar 31, 2020 | -1.20 Mn |
| Dec 31, 2019 | 166,000.00 |
| Sep 30, 2019 | -1.30 Mn |
| Jun 30, 2019 | -384,000.00 |
| Mar 31, 2019 | -429,000.00 |
| Dec 31, 2018 | 1.55 Mn |
| Sep 30, 2018 | -461,000.00 |
| Jun 30, 2018 | -828,000.00 |
| Mar 31, 2018 | -520,000.00 |
| Dec 31, 2017 | 43,000.00 |
| Sep 30, 2017 | -102,000.00 |
| Jun 30, 2017 | -135,000.00 |